BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra P, Marconi S, Gasbarrini A, Bentivoglio AR. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-9. [PMID: 23712625 DOI: 10.1002/mds.25522] [Cited by in Crossref: 159] [Cited by in F6Publishing: 129] [Article Influence: 19.9] [Reference Citation Analysis]
Number Citing Articles
1 Cassani E, Barichella M, Cancello R, Cavanna F, Iorio L, Cereda E, Bolliri C, Zampella Maria P, Bianchi F, Cestaro B, Pezzoli G. Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson's disease. Parkinsonism & Related Disorders 2015;21:389-93. [DOI: 10.1016/j.parkreldis.2015.02.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
2 Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. The Lancet Neurology 2015;14:625-39. [DOI: 10.1016/s1474-4422(15)00007-1] [Cited by in Crossref: 349] [Cited by in F6Publishing: 149] [Article Influence: 58.2] [Reference Citation Analysis]
3 Jameson KG, Hsiao EY. A novel pathway for microbial metabolism of levodopa. Nat Med 2019;25:1195-7. [PMID: 31388180 DOI: 10.1038/s41591-019-0544-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kujawska M, Jodynis-Liebert J. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut? Int J Mol Sci 2018;19:E3573. [PMID: 30424585 DOI: 10.3390/ijms19113573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
5 Li X, Feng X, Jiang Z, Jiang Z. Association of small intestinal bacterial overgrowth with Parkinson's disease: a systematic review and meta-analysis. Gut Pathog 2021;13:25. [PMID: 33863370 DOI: 10.1186/s13099-021-00420-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hasuike Y, Endo T, Koroyasu M, Matsui M, Mori C, Yamadera M, Fujimura H, Sakoda S. Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease. Med Hypotheses 2020;134:109436. [PMID: 31678900 DOI: 10.1016/j.mehy.2019.109436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Wollmer E, Klein S. A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease. International Journal of Pharmaceutics 2017;533:298-314. [DOI: 10.1016/j.ijpharm.2017.08.126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Mov Disord 2021;36:25-36. [PMID: 33314312 DOI: 10.1002/mds.28411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
9 Scheperjans F. Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle. Curr Opin Neurol 2016;29:773-80. [PMID: 27653288 DOI: 10.1097/WCO.0000000000000389] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 12.3] [Reference Citation Analysis]
10 Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018;24:3204-3221. [PMID: 30090002 DOI: 10.3748/wjg.v24.i29.3204] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 53] [Article Influence: 25.0] [Reference Citation Analysis]
11 Losurdo G, Salvatore D'Abramo F, Indellicati G, Lillo C, Ierardi E, Di Leo A. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci 2020;21:E3531. [PMID: 32429454 DOI: 10.3390/ijms21103531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
12 Borghammer P, Knudsen K, Fedorova TD, Brooks DJ. Imaging Parkinson's disease below the neck. NPJ Parkinsons Dis 2017;3:15. [PMID: 28649615 DOI: 10.1038/s41531-017-0017-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
13 Fialho A, Fialho A, Kochhar G, Schenone AL, Thota P, McCullough AJ, Shen B. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci 2018;63:412-21. [PMID: 29110161 DOI: 10.1007/s10620-017-4828-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 A. Flameling I, T. Rijkers G. Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease. In: Evrensel A, Önen Ünsalver B, editors. Gut Microbiota - Brain Axis. IntechOpen; 2018. [DOI: 10.5772/intechopen.78666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pfeiffer R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov Disord. 2013;28:1764-1765. [PMID: 24167009 DOI: 10.1002/mds.25705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
16 van Laar T, Borgemeester R. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. Parkinsonism Relat Disord 2016;33 Suppl 1:S22-7. [PMID: 27998652 DOI: 10.1016/j.parkreldis.2016.11.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
17 Csoti I, Jost WH, Reichmann H. Parkinson's disease between internal medicine and neurology. J Neural Transm (Vienna) 2016;123:3-17. [PMID: 26298728 DOI: 10.1007/s00702-015-1443-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
18 Moore H, Shpiner DS, Luca CC. Management of Motor Features in Advanced Parkinson Disease. Clin Geriatr Med 2020;36:43-52. [PMID: 31733701 DOI: 10.1016/j.cger.2019.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Khodakarami H, Ricciardi L, Contarino MF, Pahwa R, Lyons KE, Geraedts VJ, Morgante F, Leake A, Paviour D, De Angelis A, Horne M. Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor. Sensors (Basel) 2019;19:E5153. [PMID: 31775289 DOI: 10.3390/s19235153] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
20 Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM. Parkinson's disease and the gastrointestinal microbiome. J Neurol 2020;267:2507-23. [PMID: 31041582 DOI: 10.1007/s00415-019-09320-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
21 Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2017;17:94. [PMID: 29039142 DOI: 10.1007/s11910-017-0802-6] [Cited by in Crossref: 205] [Cited by in F6Publishing: 158] [Article Influence: 51.3] [Reference Citation Analysis]
22 Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: Married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5:400-404. [PMID: 25400983 DOI: 10.4291/wjgp.v5.i4.400] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
23 Grochowska M, Laskus T, Radkowski M. Gut Microbiota in Neurological Disorders. Arch Immunol Ther Exp (Warsz). 2019;67:375-383. [PMID: 31578596 DOI: 10.1007/s00005-019-00561-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
24 van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
25 Dutta SK, Verma S, Jain V, Surapaneni BK, Vinayek R, Phillips L, Nair PP. Parkinson's Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation. J Neurogastroenterol Motil 2019;25:363-76. [PMID: 31327219 DOI: 10.5056/jnm19044] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 24.5] [Reference Citation Analysis]
26 Knudsen K, Szwebs M, Hansen AK, Borghammer P. Gastric emptying in Parkinson's disease - A mini-review. Parkinsonism Relat Disord 2018;55:18-25. [PMID: 29891432 DOI: 10.1016/j.parkreldis.2018.06.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
27 Schaeffer E, Kluge A, Böttner M, Zunke F, Cossais F, Berg D, Arnold P. Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. Front Cell Dev Biol 2020;8:573696. [PMID: 33015066 DOI: 10.3389/fcell.2020.573696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
28 Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, Li J, Guan Z, Zhao H, Li W, Gao H, Zhou X, Yang L. The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease. Front Neurol 2019;10:1155. [PMID: 31781020 DOI: 10.3389/fneur.2019.01155] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
29 Yang X, Qian Y, Xu S, Song Y, Xiao Q. Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson's Disease. Front Aging Neurosci 2017;9:441. [PMID: 29358918 DOI: 10.3389/fnagi.2017.00441] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
30 McGee DJ, Lu XH, Disbrow EA. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease. J Parkinsons Dis 2018;8:367-74. [PMID: 29966206 DOI: 10.3233/JPD-181327] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
31 Menozzi E, Macnaughtan J, Schapira AHV. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med 2021;53:611-25. [PMID: 33860738 DOI: 10.1080/07853890.2021.1890330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson's disease: A culprit or a bystander? Prog Brain Res 2020;252:357-450. [PMID: 32247371 DOI: 10.1016/bs.pbr.2020.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
33 Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B. Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features. Sci China Life Sci 2017;60:1223-33. [DOI: 10.1007/s11427-016-9001-4] [Cited by in Crossref: 126] [Cited by in F6Publishing: 112] [Article Influence: 31.5] [Reference Citation Analysis]
34 Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson's Disease. Curr Treat Options Neurol. 2018;20:54. [PMID: 30361783 DOI: 10.1007/s11940-018-0539-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
35 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015;21:10609-20. [PMID: 26457021 DOI: 10.3748/wjg.v21.i37.10609] [Cited by in CrossRef: 248] [Cited by in F6Publishing: 207] [Article Influence: 49.6] [Reference Citation Analysis]
36 Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45:604-616. [PMID: 28078798 DOI: 10.1111/apt.13928] [Cited by in Crossref: 78] [Cited by in F6Publishing: 58] [Article Influence: 19.5] [Reference Citation Analysis]
37 Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson's disease. World J Gastroenterol 2016;22:5742-52. [PMID: 27433087 DOI: 10.3748/wjg.v22.i25.5742] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
38 Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 2015;15:723-32. [DOI: 10.1586/14737175.2015.1051468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
39 Beckers M, Lees AJ, Nutt JG, Bloem BR. Turning Back the Clock in Parkinson's Disease: Practical Recommendations for Managing Diurnal Symptom Worsening. J Parkinsons Dis 2021;11:1471-3. [PMID: 33967059 DOI: 10.3233/JPD-212711] [Reference Citation Analysis]
40 Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal Dysfunction in Parkinson's Disease. J Clin Med 2021;10:493. [PMID: 33572547 DOI: 10.3390/jcm10030493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
41 Li XQ, Feng X, Jiang Z. Comment on "Association of Intestinal Disorders with Parkinson's Disease and Alzheimer's Disease: A Systematic Review and Meta-Analysis". ACS Chem Neurosci 2021;12:810. [PMID: 33503364 DOI: 10.1021/acschemneuro.0c00703] [Reference Citation Analysis]
42 Chiang HL, Lin CH. Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. J Mov Disord 2019;12:67-83. [PMID: 31158941 DOI: 10.14802/jmd.18067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
43 Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, Chen SD, Xiao Q. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. 2018;70:194-202. [PMID: 29501802 DOI: 10.1016/j.bbi.2018.02.016] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 42.0] [Reference Citation Analysis]
44 Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141-146. [PMID: 24406476 DOI: 10.1097/mog.0000000000000040] [Cited by in Crossref: 50] [Cited by in F6Publishing: 18] [Article Influence: 7.1] [Reference Citation Analysis]
45 Nair AT, Ramachandran V, Joghee NM, Antony S, Ramalingam G. Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review. J Neurogastroenterol Motil 2018;24:30-42. [PMID: 29291606 DOI: 10.5056/jnm17105] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 19.7] [Reference Citation Analysis]
46 Kim JS, Sung HY. Gastrointestinal Autonomic Dysfunction in Patients with Parkinson's Disease. J Mov Disord 2015;8:76-82. [PMID: 26090079 DOI: 10.14802/jmd.15008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
47 Pfeiffer RF. Autonomic Dysfunction in Parkinson's Disease. Neurotherapeutics 2020;17:1464-79. [PMID: 32789741 DOI: 10.1007/s13311-020-00897-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
48 Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord 2014;29:976-9. [PMID: 24753353 DOI: 10.1002/mds.25882] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
49 Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, Ducarmon QR, Keller JJ, Kuijper EJ, Contarino MF. Fecal Microbiota Transplantation in Neurological Disorders. Front Cell Infect Microbiol 2020;10:98. [PMID: 32266160 DOI: 10.3389/fcimb.2020.00098] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 47.0] [Reference Citation Analysis]
50 Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye AD, Kaye AM, Kaye JS, Kaye RJ, M Sheth M, Viswanath O, Urits I. Chronic Pain Treatment Strategies in Parkinson's Disease. Neurol Int 2020;12:61-76. [PMID: 33218135 DOI: 10.3390/neurolint12030014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
51 Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, Dastamani M, Bogdanos DP, Deretzi G, Kountouras J. H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16-24. [PMID: 30308319 DOI: 10.1016/j.clineuro.2018.09.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
52 Pietrucci D, Teofani A, Unida V, Cerroni R, Biocca S, Stefani A, Desideri A. Can Gut Microbiota Be a Good Predictor for Parkinson's Disease? A Machine Learning Approach. Brain Sci 2020;10:E242. [PMID: 32325848 DOI: 10.3390/brainsci10040242] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
53 Scheperjans F, Derkinderen P, Borghammer P. The Gut and Parkinson's Disease: Hype or Hope? J Parkinsons Dis 2018;8:S31-9. [PMID: 30584161 DOI: 10.3233/JPD-181477] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 18.5] [Reference Citation Analysis]
54 Barboza JL, Okun MS, Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opin Pharmacother 2015;16:2449-64. [PMID: 26374094 DOI: 10.1517/14656566.2015.1086747] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
55 Su A, Gandhy R, Barlow C, Triadafilopoulos G. A practical review of gastrointestinal manifestations in Parkinson's disease. Parkinsonism & Related Disorders 2017;39:17-26. [DOI: 10.1016/j.parkreldis.2017.02.029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
56 Rezaie A, Buresi M, Rao S. Response to Paterson et al. Am J Gastroenterol 2017;112:1889-92. [PMID: 29215623 DOI: 10.1038/ajg.2017.373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Johnson ME, Stringer A, Bobrovskaya L. Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson’s disease. NeuroToxicology 2018;65:174-85. [DOI: 10.1016/j.neuro.2018.02.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
58 Calvani R, Picca A, Lo Monaco MR, Landi F, Bernabei R, Marzetti E. Of Microbes and Minds: A Narrative Review on the Second Brain Aging. Front Med (Lausanne) 2018;5:53. [PMID: 29552561 DOI: 10.3389/fmed.2018.00053] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
59 Brown EG, Goldman SM. Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond. Neurotherapeutics 2020;17:1406-17. [PMID: 33034846 DOI: 10.1007/s13311-020-00942-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, Dallio M, Federico A, Romano M. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med 2020;9:E3887. [PMID: 33265933 DOI: 10.3390/jcm9123887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
61 Rani L, Mondal AC. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications. Neurosci Res 2021;168:100-12. [PMID: 33417973 DOI: 10.1016/j.neures.2021.01.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Kadowaki A, Saga R, Lin Y, Sato W, Yamamura T. Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. Brain 2019;142:916-31. [PMID: 30770703 DOI: 10.1093/brain/awz012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
63 Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord 2020;35:1438-47. [PMID: 32357260 DOI: 10.1002/mds.28068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
64 Kim Y, Lee C, Kim S, Jang J, Lee S, Lee S. Risk of Parkinson’s disease after colectomy: longitudinal follow-up study using a national sample cohort. J Neurol 2020;267:513-21. [DOI: 10.1007/s00415-019-09617-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. J Neurol 2018;265:12-23. [PMID: 29018983 DOI: 10.1007/s00415-017-8639-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
66 Leggio L, Paternò G, Vivarelli S, L'Episcopo F, Tirolo C, Raciti G, Pappalardo F, Giachino C, Caniglia S, Serapide MF, Marchetti B, Iraci N. Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease. Biomolecules 2020;10:E1327. [PMID: 32948090 DOI: 10.3390/biom10091327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
67 Nunes JM, Fillis T, Page MJ, Venter C, Lancry O, Kell DB, Windberger U, Pretorius E. Gingipain R1 and Lipopolysaccharide From Porphyromonas gingivalis Have Major Effects on Blood Clot Morphology and Mechanics. Front Immunol 2020;11:1551. [PMID: 32793214 DOI: 10.3389/fimmu.2020.01551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Ilie OD, Ciobica A, McKenna J, Doroftei B, Mavroudis I. Minireview on the Relations between Gut Microflora and Parkinson's Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities. Oxid Med Cell Longev 2020;2020:4518023. [PMID: 32089768 DOI: 10.1155/2020/4518023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
69 Kenna JE, Bakeberg MC, Gorecki AM, Chin Yen Tay A, Winter S, Mastaglia FL, Anderton RS. Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort. Mov Disord Clin Pract 2021;8:245-53. [PMID: 33553495 DOI: 10.1002/mdc3.13134] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 2019;364:eaau6323. [PMID: 31196984 DOI: 10.1126/science.aau6323] [Cited by in Crossref: 159] [Cited by in F6Publishing: 117] [Article Influence: 79.5] [Reference Citation Analysis]
71 Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Tan CT. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:535-540. [PMID: 24637123 DOI: 10.1016/j.parkreldis.2014.02.019] [Cited by in Crossref: 136] [Cited by in F6Publishing: 117] [Article Influence: 19.4] [Reference Citation Analysis]
72 Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, Martin ER, Haines JL, Pericak-Vance MA, Vance JM, Scott WK. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord 2015;30:560-6. [PMID: 25545356 DOI: 10.1002/mds.26117] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
73 Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Loke MF, Vadivelu JS, Ibrahim N, Yong HS, Tan CT, Fox SH, Lang AE, Lim S. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism & Related Disorders 2015;21:221-5. [DOI: 10.1016/j.parkreldis.2014.12.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
74 Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019;10:e00078. [PMID: 31584459 DOI: 10.14309/ctg.0000000000000078] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 23.0] [Reference Citation Analysis]
75 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa Pharmacokinetics. J Parkinsons Dis 2021;11:61-9. [PMID: 33164946 DOI: 10.3233/JPD-202298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
76 Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM. Implications of the Gut Microbiome in Parkinson's Disease. Mov Disord 2020;35:921-33. [DOI: 10.1002/mds.28004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
77 Tan AH, Chong CW, Lim SY, Yap IKS, Teh CSJ, Loke MF, Song SL, Tan JY, Ang BH, Tan YQ, Kho MT, Bowman J, Mahadeva S, Yong HS, Lang AE. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. Ann Neurol 2021;89:546-59. [PMID: 33274480 DOI: 10.1002/ana.25982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
78 Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, Tanner CM. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80. [PMID: 24838182 DOI: 10.1002/mds.25895] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
79 Chung KA, Pfeiffer RF. Gastrointestinal dysfunction in the synucleinopathies. Clin Auton Res 2021;31:77-99. [PMID: 33247399 DOI: 10.1007/s10286-020-00745-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
80 Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH, Egert M. Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis 2019;5:28. [PMID: 31815177 DOI: 10.1038/s41531-019-0100-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
81 Liu X, Liu S, Tang Y, Pu Z, Xiao H, Gao J, Yin Q, Jia Y, Bai Q. Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease. Neurochem Res 2021;46:1514-39. [PMID: 33719004 DOI: 10.1007/s11064-021-03293-2] [Reference Citation Analysis]
82 Fasano A, Bove F, Gabrielli M, Ragazzoni E, Fortuna S, Tortora A, Zocco MA, Marconi S, Gasbarrini A, Bentivoglio AR. Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth. Clinical Neuropharmacology 2014;37:91-5. [DOI: 10.1097/wnf.0000000000000034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
83 Vizcarra JA, Wilson-Perez HE, Fasano A, Espay AJ. Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial. Parkinsonism Relat Disord 2018;54:110-2. [PMID: 29636215 DOI: 10.1016/j.parkreldis.2018.04.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
84 Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018;90:e404-11. [PMID: 29298852 DOI: 10.1212/WNL.0000000000004888] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
85 Johnson M, Salvatore M, Maiolo S, Bobrovskaya L. Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson’s progression: Evidence from clinical studies and neurotoxin models. Progress in Neurobiology 2018;165-167:1-25. [DOI: 10.1016/j.pneurobio.2018.01.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
86 Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinsons Dis 2017;3:3. [PMID: 28649603 DOI: 10.1038/s41531-016-0002-0] [Cited by in Crossref: 199] [Cited by in F6Publishing: 173] [Article Influence: 49.8] [Reference Citation Analysis]
87 Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord 2020;76:63-71. [PMID: 32461054 DOI: 10.1016/j.parkreldis.2020.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
88 Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When? J Parkinsons Dis 2020;10:S65-73. [PMID: 32651333 DOI: 10.3233/JPD-202104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
89 Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter 2017;22:e12398. [DOI: 10.1111/hel.12398] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 10.5] [Reference Citation Analysis]
90 Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, Li HH. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease. J Neural Transm (Vienna) 2016;123:1381-6. [PMID: 27589873 DOI: 10.1007/s00702-016-1612-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
91 Ramprasad C, Douglas JY, Moshiree B. Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects. Curr Treat Options Gastroenterol 2018;16:489-510. [PMID: 30361854 DOI: 10.1007/s11938-018-0201-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
92 Dogra N, Mani RJ, Katare DP. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease. Cell Mol Neurobiol 2021. [PMID: 33649989 DOI: 10.1007/s10571-021-01066-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
93 Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF, Zhou CL. Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation. Microb Cell Fact 2021;20:98. [PMID: 33985520 DOI: 10.1186/s12934-021-01589-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;30:1351-60. [PMID: 26179554 DOI: 10.1002/mds.26307] [Cited by in Crossref: 494] [Cited by in F6Publishing: 412] [Article Influence: 82.3] [Reference Citation Analysis]
95 van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019;10:310. [PMID: 30659181 DOI: 10.1038/s41467-019-08294-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 106] [Article Influence: 63.5] [Reference Citation Analysis]
96 Roy Sarkar S, Banerjee S. Gut microbiota in neurodegenerative disorders. Journal of Neuroimmunology 2019;328:98-104. [DOI: 10.1016/j.jneuroim.2019.01.004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 45.0] [Reference Citation Analysis]
97 Castillo-Álvarez F, Marzo-Sola ME. Role of the gut microbiota in the development of various neurological diseases. Neurologia (Engl Ed) 2019:S0213-4853(19)30082-9. [PMID: 31340904 DOI: 10.1016/j.nrl.2019.03.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
98 Zhang Y, Li J, Zhang X, Song D, Tian T. Advances of Mechanisms-Related Metabolomics in Parkinson's Disease. Front Neurosci 2021;15:614251. [PMID: 33613180 DOI: 10.3389/fnins.2021.614251] [Reference Citation Analysis]
99 Tan AH, Lim S, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Mov Disord 2020;35:2250-60. [DOI: 10.1002/mds.28248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
100 Su A, Gandhy R, Barlow C, Triadafilopoulos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson's disease who present with functional gastrointestinal symptoms. BMJ Open Gastroenterol 2017;4:e000132. [PMID: 28321329 DOI: 10.1136/bmjgast-2017-000132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
101 Brown EG, Tanner CM, Goldman SM. The Microbiome in Neurodegenerative Disease. Curr Geri Rep 2018;7:81-91. [DOI: 10.1007/s13670-018-0240-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Stocchi F, Torti M. Constipation in Parkinson's Disease. Int Rev Neurobiol 2017;134:811-26. [PMID: 28805584 DOI: 10.1016/bs.irn.2017.06.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
103 Foo ASC, Soong TW, Yeo TT, Lim KL. Mitochondrial Dysfunction and Parkinson's Disease-Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy. Front Aging Neurosci 2020;12:89. [PMID: 32308618 DOI: 10.3389/fnagi.2020.00089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
104 Scheperjans F. Can microbiota research change our understanding of neurodegenerative diseases? Neurodegener Dis Manag 2016;6:81-5. [PMID: 27033377 DOI: 10.2217/nmt-2015-0012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
105 Moustafa SA, Mohamed S, Dawood A, Azar J, Elmorsy E, Rizk NAM, Salama M. Gut brain axis: an insight into microbiota role in Parkinson's disease. Metab Brain Dis 2021. [PMID: 34370175 DOI: 10.1007/s11011-021-00808-2] [Reference Citation Analysis]
106 de Waal GM, Engelbrecht L, Davis T, de Villiers WJS, Kell DB, Pretorius E. Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson's Disease, Alzheimer's Disease and Type 2 Diabetes Mellitus. Sci Rep 2018;8:16798. [PMID: 30429533 DOI: 10.1038/s41598-018-35009-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
107 Binvignat O, Olloquequi J. Excitotoxicity as a Target Against Neurodegenerative Processes. Curr Pharm Des 2020;26:1251-62. [PMID: 31931694 DOI: 10.2174/1381612826666200113162641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
108 Sherwin E, Dinan TG, Cryan JF. Recent developments in understanding the role of the gut microbiota in brain health and disease. Ann N Y Acad Sci 2018;1420:5-25. [PMID: 28768369 DOI: 10.1111/nyas.13416] [Cited by in Crossref: 110] [Cited by in F6Publishing: 80] [Article Influence: 27.5] [Reference Citation Analysis]
109 Yemula N, Dietrich C, Dostal V, Hornberger M. Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota. J Parkinsons Dis 2021. [PMID: 34250955 DOI: 10.3233/JPD-212707] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Madore C, Yin Z, Leibowitz J, Butovsky O. Microglia, Lifestyle Stress, and Neurodegeneration. Immunity 2020;52:222-40. [PMID: 31924476 DOI: 10.1016/j.immuni.2019.12.003] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 53.0] [Reference Citation Analysis]
111 Cheng X, Zhang L, Xie NC, Xu HL, Lian YJ. Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries. J Thromb Haemost 2017;15:304-11. [PMID: 27930853 DOI: 10.1111/jth.13583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
112 Ma K, Xiong N, Shen Y, Han C, Liu L, Zhang G, Wang L, Guo S, Guo X, Xia Y, Wan F, Huang J, Lin Z, Wang T. Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects. Front Aging Neurosci 2018;10:1. [PMID: 29403371 DOI: 10.3389/fnagi.2018.00001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
113 Soliman H, Coffin B, Gourcerol G. Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management. Brain Sci 2021;11:831. [PMID: 34201699 DOI: 10.3390/brainsci11070831] [Reference Citation Analysis]
114 Cerovic M, Forloni G, Balducci C. Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer's Disease? Front Aging Neurosci 2019;11:284. [PMID: 31680937 DOI: 10.3389/fnagi.2019.00284] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
115 Yoo D, Lim Y, Son Y, Rho H, Shin C, Ahn TB. Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson's disease. Sci Rep 2021;11:12489. [PMID: 34127758 DOI: 10.1038/s41598-021-92029-x] [Reference Citation Analysis]
116 Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson's disease. Parkinsonism Relat Disord 2017;38:1-7. [PMID: 28202372 DOI: 10.1016/j.parkreldis.2017.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 25.5] [Reference Citation Analysis]
117 Fu P, Gao M, Yung KKL. Association of Intestinal Disorders with Parkinson’s Disease and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. ACS Chem Neurosci 2020;11:395-405. [DOI: 10.1021/acschemneuro.9b00607] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
118 Lewitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics: Levodopa Pharmacokinetics and Pharmacodynamics. Mov Disord 2015;30:64-72. [DOI: 10.1002/mds.26082] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 18.9] [Reference Citation Analysis]
119 Gallop A, Weagley J, Paracha SU, Grossberg G. The Role of The Gut Microbiome in Parkinson's Disease. J Geriatr Psychiatry Neurol 2021;34:253-62. [PMID: 34219519 DOI: 10.1177/08919887211018268] [Reference Citation Analysis]
120 Gonçalves AM, Pereira-Santos AR, Esteves AR, Cardoso SM, Empadinhas N. The Mitochondrial Ribosome: A World of Opportunities for Mitochondrial Dysfunction Toward Parkinson's Disease. Antioxid Redox Signal 2021;34:694-711. [PMID: 32098485 DOI: 10.1089/ars.2019.7997] [Reference Citation Analysis]
121 Kowalski K, Mulak A. Brain-Gut-Microbiota Axis in Alzheimer's Disease. J Neurogastroenterol Motil 2019;25:48-60. [PMID: 30646475 DOI: 10.5056/jnm18087] [Cited by in Crossref: 212] [Cited by in F6Publishing: 159] [Article Influence: 106.0] [Reference Citation Analysis]
122 Jiang T, Li G, Xu J, Gao S, Chen X. The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit? Front Immunol 2018;9:2047. [PMID: 30319601 DOI: 10.3389/fimmu.2018.02047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
123 Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol 2015;11:625-36. [DOI: 10.1038/nrneurol.2015.197] [Cited by in Crossref: 256] [Cited by in F6Publishing: 222] [Article Influence: 42.7] [Reference Citation Analysis]
124 Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A, Ohno K, Hirayama M. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease. PLoS One 2015;10:e0142164. [PMID: 26539989 DOI: 10.1371/journal.pone.0142164] [Cited by in Crossref: 209] [Cited by in F6Publishing: 184] [Article Influence: 34.8] [Reference Citation Analysis]
125 Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. Parkinsonism Relat Disord 2016;27:1-8. [PMID: 27013171 DOI: 10.1016/j.parkreldis.2016.03.012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 85] [Article Influence: 20.4] [Reference Citation Analysis]
126 Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J Exp Med 2019;216:41-59. [PMID: 30385457 DOI: 10.1084/jem.20180794] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 29.3] [Reference Citation Analysis]
127 Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola‐rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2014;30:350-8. [DOI: 10.1002/mds.26069] [Cited by in Crossref: 811] [Cited by in F6Publishing: 685] [Article Influence: 115.9] [Reference Citation Analysis]
128 Morgan JC, Fox SH. Treating the Motor Symptoms of Parkinson Disease. Continuum (Minneap Minn) 2016;22:1064-85. [PMID: 27495198 DOI: 10.1212/CON.0000000000000355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
129 Kalampokini S, Becker A, Fassbender K, Lyros E, Unger MM. Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions. Parkinsons Dis 2019;2019:7535472. [PMID: 31534664 DOI: 10.1155/2019/7535472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]